Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL588513 | 1.00 | AXL (0.50) | AXLIMPDH2PDPK1ADORA2AADORA2B | |
| Hydrochloric Acid SCHEMBL588415 | 0.98 | AXL (0.49) | AXLIMPDH2PDPK1ADORA2AADORA2B | |
| SCHEMBL29644057 | 0.84 | GSK3B (0.56) | AXLIMPDH2PDPK1ADORA2AADORA2B | |
| SCHEMBL266855 | 0.84 | GSK3B (0.56) | AXLIMPDH2PDPK1ADORA2AADORA2B | |
| SCHEMBL922069 | 0.81 | PDPK1 (0.65) | AXLPDPK1JAK2FGFR1FGFR2 | |
| SCHEMBL12247 | 0.79 | ITK (0.53) | ADORA2AADORA2BCYP1A2 | |
| SCHEMBL31552439 | 0.79 | ITK (0.53) | ADORA2AADORA2BCYP1A2 | |
| SCHEMBL10131378 | 0.76 | ADORA2A (0.46) | PDPK1ADORA2AADORA2BJAK2FGFR1 | |
| SCHEMBL21937470 | 0.76 | ADORA2A (0.46) | PDPK1ADORA2AADORA2BJAK2FGFR1 | |
| SCHEMBL8212257 | 0.76 | MAP2K4 (0.56) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4603488-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-08-20 | — | — | EP | disclosed |
| US-20240336592-A1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA PLC (GB) | 2024-10-10 | — | — | US | disclosed |
| EP-4426688-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | Redx Pharma Plc (GB) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024080780-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-04-18 | — | — | WO | disclosed |
| WO-2023079291-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2023-05-11 | — | — | WO | disclosed |
| EP-3983389-A1 | COMPOUNDS FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336592-A1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | DDR1, DDR2, DDRGK1 | AXL 295/4885IMPDH2 2272/4885PDPK1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.